Literature DB >> 12520754

[Research advances on effect of arsenic trioxide on tumor].

Chun-qiong Feng1, Wen-li Ma, Wen-ling Zheng.   

Abstract

Arsenic compounds are natural substances that have been used medically for more than 2,400 years in China. Since 1990s, Chinese physicians have began to use arsenic trioxide in treating the patients with acute promyelocytic leukemia (APL), and the results showed that arsenic trioxide was effective on APL patients. Further study of arsenic trioxide demonstrated that arsenic trioxide was safe and effective not only on patients with leukemia, but also on patients with many other kinds of malignant cancers. Arsenic trioxide exerted its anti-cancer effects mainly by inhibiting the cell growth and angiogenesis, inducing the cell partial cytodifferentiation and apoptosis, etc. In addition, this review looked forward to the prospect of application of gene chip, a newly developed and powerful technology in analysis of gene expression profile, in elucidation of the mechanism of arsenic trioxide on tumor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12520754

Source DB:  PubMed          Journal:  Ai Zheng


  3 in total

1.  Effect of arsenic trioxide on human hepatocarcinoma in nude mice.

Authors:  Hong-Yu Xu; You-Lin Yang; Shu-Mei Liu; Li Bi; Shu-Xiang Chen
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

2.  Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide.

Authors:  Qin-Shu Shao; Zai-Yuan Ye; Zhi-Qiang Ling; Jin-Jing Ke
Journal:  World J Gastroenterol       Date:  2005-06-14       Impact factor: 5.742

3.  Construction of a BALB/c-Nu Mouse Model of Invasive Bladder Carcinoma and Preliminary Studies on the Treatment of Bladder Tumors through Internal Iliac Arterial Infusion of Albumin-Bound Arsenic Trioxide (As2O3).

Authors:  Yunlong Li; Guopeng Yu; Qiaoxing Li; Weilu Wang; Xiangqian Shen; Hua Liu; Ruijiang Liu
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.